Physician profile
Saif U Syed
NPI 1053363341
$4,130.63
in general payments reported to CMS, 2019-2025
33 companies · $922 in 2025
The $922 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $182 · 2021: $386 · 2022: $592 · 2023: $589 · 2024: $804 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,315.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $810.24 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $536.44 | 2019-2025 | |
| Janssen Biotech, INC. | $378.72 | 2019-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $289.99 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $256.63 | 2019-2025 | |
| Pfizer INC. | $226.21 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $207.12 | 2019-2025 | Libtayo, Dupixent |
| Galderma Laboratories, L.P. | $202.22 | 2019-2025 | Aklief, Nemluvio, Epsolay |
| E.R. Squibb & Sons, L.L.C. | $162.56 | 2024-2025 | Reblozyl, Sotyktu |
| Organon LLC | $136.62 | 2025 | Vtama |
| Leo Pharma INC. | $129.97 | 2019-2024 | Adbry |
| Incyte Corporation | $84.74 | 2021-2025 | Opzelura |
| Hill Dermaceuticals, INC. | $76.70 | 2021 | |
| Ucb, INC. | $75.75 | 2019-2024 | Bimzelx |
| Biofrontera INC. | $58.96 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $56.46 | 2025 | Puraply Wound Matrix, Via Matrix |
| Lilly USA, LLC | $52.56 | 2020-2022 | |
| Almirall LLC | $50.87 | 2019-2025 | Klisyri |
| Arcutis Biotherapeutics, INC. | $41.98 | 2023-2025 | Zoryve |
| Celgene Corporation | $33.90 | 2019 | |
| Boston Scientific Corporation | $31.26 | 2025 | Varithena Administration Pack |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.84 | 2025 | Spevigo |
| Kerecis Limited | $25.84 | 2022-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Convatec INC. | $21.95 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.80 | 2021 | |
| Kyowa Kirin, INC. | $20.60 | 2022 | |
| Vyne Pharmaceuticals INC. | $19.83 | 2020 | |
| Integra Lifesciences Corporation | $18.56 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Genentech USA, INC. | $17.88 | 2021 | |
| Lumenis, INC | $15.55 | 2021 | |
| Verrica Pharmaceuticals INC. | $14.90 | 2023 | Ycanth |
| Biowound Solutions, INC. | $14.71 | 2025 | Bio-Connekt |
| Tris Pharma INC | $13.27 | 2023 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saif Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.